Anika Therapeutics, Inc. Proceeds from Sale and Maturity of Marketable Securities
Anika Therapeutics, Inc. (ANIK) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2024-03-15
- Anika Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2022-12-31 was $0.00.
- Anika Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2022-09-30 was $0.00.
- Anika Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2022-06-30 was $0.00.
- Anika Therapeutics, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Anika Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2023 was $0.00.
- Anika Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Anika Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2021 was $2.50M, a 94.44% decline from fiscal 2020.
- Anika Therapeutics, Inc. proceeds from sale and maturity of marketable securities for fiscal 2020 was $45.00M, a 69.26% decline from fiscal 2019.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-15 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | $0.00 10-K · filed 2024-03-15 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | $0.00 derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-06 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | $0.00 derived: sum of 4 quarters · filed 2024-03-15 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $0.00 derived: sum of 3 quarters · filed 2024-03-15 | $2.50M 10-K · filed 2024-03-15 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $2.50M 10-Q · filed 2022-11-09 | $20.50M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.50M 10-Q · filed 2022-08-04 | $20.50M derived: sum of 3 quarters · filed 2023-03-16 | $27.50M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $2.50M 10-Q · filed 2022-05-06 | $20.50M derived: sum of 2 quarters · filed 2023-03-16 | $27.50M derived: sum of 3 quarters · filed 2023-03-16 | $32.51M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $25.00M derived: sum of 2 quarters · filed 2023-03-16 | $30.01M derived: sum of 3 quarters · filed 2023-03-16 | $45.00M 10-K · filed 2023-03-16 |
| 2020-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $12.01M derived: sum of 2 quarters · filed 2021-11-05 | $27.00M 10-Q · filed 2021-11-05 | $85.77M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-06-30 | $5.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $20.00M 10-Q · filed 2021-08-06 | $78.77M derived: sum of 3 quarters · filed 2022-03-11 | $93.77M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-03-31 | $14.99M 10-Q · filed 2021-05-07 | $73.76M derived: sum of 2 quarters · filed 2022-03-11 | $88.76M derived: sum of 3 quarters · filed 2022-03-11 | $103.26M derived: sum of 4 quarters · filed 2022-03-11 |
| 2019-12-31 | $58.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $73.77M derived: sum of 2 quarters · filed 2022-03-11 | $88.27M derived: sum of 3 quarters · filed 2022-03-11 | $146.37M 10-K · filed 2022-03-11 |
| 2019-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $29.50M derived: sum of 2 quarters · filed 2020-11-05 | $87.59M 10-Q · filed 2020-11-05 | $99.09M derived: sum of 4 quarters · filed 2021-04-26 |
| 2019-06-30 | $14.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $72.59M 10-Q · filed 2020-08-07 | $84.09M derived: sum of 3 quarters · filed 2021-04-26 | $93.84M derived: sum of 4 quarters · filed 2021-04-26 |
| 2019-03-31 | $58.09M 10-Q · filed 2020-05-22 | $69.59M derived: sum of 2 quarters · filed 2021-04-26 | $79.34M derived: sum of 3 quarters · filed 2021-04-26 | $88.84M derived: sum of 4 quarters · filed 2021-04-26 |
| 2018-12-31 | $11.50M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-26 | $21.25M derived: sum of 2 quarters · filed 2021-04-26 | $30.75M derived: sum of 3 quarters · filed 2021-04-26 | $46.00M 10-K/A · filed 2021-04-26 |
| 2018-09-30 | $9.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | $19.25M derived: sum of 2 quarters · filed 2019-10-28 | $34.50M 10-Q · filed 2019-10-28 | $44.75M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-06-30 | $9.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-26 | $24.75M 10-Q · filed 2019-07-26 | $35.00M derived: sum of 3 quarters · filed 2020-03-06 | $46.25M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-03-31 | $15.25M 10-Q · filed 2019-05-06 | $25.50M derived: sum of 2 quarters · filed 2020-03-06 | $36.75M derived: sum of 3 quarters · filed 2020-03-06 | $44.25M derived: sum of 4 quarters · filed 2020-03-06 |
| 2017-12-31 | $10.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $21.50M derived: sum of 2 quarters · filed 2020-03-06 | $29.00M derived: sum of 3 quarters · filed 2020-03-06 | $41.50M 10-K · filed 2020-03-06 |
| 2017-09-30 | $11.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $18.75M derived: sum of 2 quarters · filed 2018-10-26 | $31.25M 10-Q · filed 2018-10-26 | $40.00M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-31 | $20.00M 10-Q · filed 2018-07-31 | $28.75M derived: sum of 3 quarters · filed 2019-02-27 | $38.75M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $12.50M 10-Q · filed 2018-05-10 | $21.25M derived: sum of 2 quarters · filed 2019-02-27 | $31.25M derived: sum of 3 quarters · filed 2019-02-27 | $44.75M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $18.75M derived: sum of 2 quarters · filed 2019-02-27 | $32.25M derived: sum of 3 quarters · filed 2019-02-27 | $46.50M 10-K · filed 2019-02-27 |
| 2016-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-27 | $23.50M derived: sum of 2 quarters · filed 2017-10-27 | $37.75M 10-Q · filed 2017-10-27 | $47.25M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-06-30 | $13.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $27.75M 10-Q · filed 2017-07-28 | $37.25M derived: sum of 3 quarters · filed 2018-02-27 | $41.75M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $14.25M 10-Q · filed 2017-05-04 | $23.75M derived: sum of 2 quarters · filed 2018-02-27 | $28.25M derived: sum of 3 quarters · filed 2018-02-27 | $37.00M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | $9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $14.00M derived: sum of 2 quarters · filed 2018-02-27 | $22.75M derived: sum of 3 quarters · filed 2018-02-27 | $24.25M 10-K · filed 2018-02-27 |
| 2015-09-30 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $13.25M derived: sum of 2 quarters · filed 2016-11-01 | $14.75M 10-Q · filed 2016-11-01 | |
| 2015-06-30 | $8.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $10.25M 10-Q · filed 2016-08-01 | ||
| 2015-03-31 | $1.50M 10-Q · filed 2016-05-03 | |||
| 2014-12-31 | $20.00M 10-K · filed 2017-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |